Optimal Dog Visits

November 17, 2020 updated by: University of Aarhus

The aim of this project is to study how an the intensity of dog contact during dog visits in nursing homes can affect the immediate response to, and the general effect of the visits, and whether the residents' level of cognitive impairment affects the response and benefit of dog visits.

The participants are randomly assigned to receive one type of visits (12 visits in total) out of three possible visit types (1: visit with a dog; 2: visit with a dog, including a planned activity, 3 visit without a dog, including a planned activity). The residents received 2 visits per week for 6 weeks. The behaviour of the participants during visits is recorded. Before and after the intervention period, participants are scores on psychometric scales for cognitive impairment level, daily function level and symptoms of depression.

Study Overview

Status

Completed

Conditions

Study Type

Interventional

Enrollment (Actual)

186

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

60 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

• Being able to sit up during the visits

Exclusion Criteria:

  • Dog allergy
  • Fear of dogs
  • Health problems that make participation unadvisable

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: 1: Dog visit with a dog, no additional activity (D)
The nursing home resident receives 12 10-minute visits in their own room. The visitor is accompanied with a dog, and the resident can touch the dog. Apart from the visitor, an observer is present.
An visitor visits the participant with a dog
Experimental: 2: Dog visit with an additional activity (DA)

The nursing home resident receives 12 10-minute visits in their own room. The visitor is accompanied with a dog, and the resident can touch the dog. During the visit, the visitor offers the resident to participate in an activity that involves interacting with the dog.

Apart from the visitor, an observer is present.

An visitor visits the participant with a dog
In each visit the visitor invites the participant to engage in an activitty
Active Comparator: 3: Visit without dog, with an additional activity (A)

The nursing home resident receives 12 10-minute visits in their own room. During the visit, the visitor offers the resident to participate in an activity.

Apart from the visitor, an observer is present, but no dog is present..

In each visit the visitor invites the participant to engage in an activitty

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Behavioural response during visits
Time Frame: Behaviour is recorded in all of the 12 visits in the 6 week intervention period
The behaviour of the residents is recorded by direct observation using continuous recording. In all visits, the frequency and duration of talk and physical contact to the persons present are recorded. Talk is classified into talk about the dog and/or activity, depending on the visit type. In visits with dogs (D, DA), the frequency and duration of physical contact and talk directed to the dog are recorded, and in visits involving an activity (DA, A), the frequency and duration of the residents' involvement in the activity are recorded.
Behaviour is recorded in all of the 12 visits in the 6 week intervention period

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cognitive impairment level, before intervention
Time Frame: This measure is obtained in the week preceeding the intervention period (6 weeks, 2 visits )
All participants were scored on the Mini-Mental State Examination (MMSE), which gives information about the participants' cognitive status.The MMSE score has a minimum and maximum value of 0 and 30, respectively. The lower the score, the more severe the cognitively impairment level.
This measure is obtained in the week preceeding the intervention period (6 weeks, 2 visits )
Daily function level, before intervention
Time Frame: This measure is obtained in the week preceeding the intervention period (6 weeks, 2 visits )
All participants were scored on The Gottfries-Bråne-Steen Scale (GBS), which is an evaluation of disabilities, language, psychiatric symptoms, average daily living function, and behaviour of the participants. The GBS score has a minimum and maximum value of 0 and 156, respectively. The lower the score, the more well-functioning the patient.
This measure is obtained in the week preceeding the intervention period (6 weeks, 2 visits )
Symptoms of depression, before intervention
Time Frame: This measure is obtained in the week preceeding the intervention period (6 weeks, 2 visits )
All participants were scored on the Geriatric Depression Scale (GDS), to screen for symptoms of depression. The GDS score has a minimum and maximum value of 0 and 15, respectively.A high score indicates more symptoms of depression.
This measure is obtained in the week preceeding the intervention period (6 weeks, 2 visits )
Cognitive impairment level, after intervention
Time Frame: This measure is obtained in the week following the intervention period (6 weeks, 2 visits )
All participants were scored on the Mini-Mental State Examination (MMSE), which gives information about the participants' cognitive status. The MMSE score has a minimum and maximum value of 0 and 30, respectively. The lower the score, the more severe the cognitively impairment level.
This measure is obtained in the week following the intervention period (6 weeks, 2 visits )
Daily function level,, after intervention
Time Frame: This measure is obtained in the week following the intervention period (6 weeks, 2 visits )
All participants were scored on The Gottfries-Bråne-Steen Scale (GBS), which is an evaluation of disabilities, language, psychiatric symptoms, average daily living function, and behaviour of the participants. The GBS score has a minimum and maximum value of 0 and 156, respectively. The lower the score, the more well-functioning the patient.
This measure is obtained in the week following the intervention period (6 weeks, 2 visits )
Symptoms of depression, after intervention
Time Frame: This measure is obtained in the week following the intervention period (6 weeks, 2 visits )
All participants were scored on the Geriatric Depression Scale (GDS), to screen for symptoms of depression. The GDS score has a minimum and maximum value of 0 and 15, respectively.A high score indicates more symptoms of depression.
This measure is obtained in the week following the intervention period (6 weeks, 2 visits )

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Karen Thodberg, University of Aarhus

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2015

Primary Completion (Actual)

November 1, 2017

Study Completion (Actual)

November 1, 2017

Study Registration Dates

First Submitted

November 16, 2020

First Submitted That Met QC Criteria

November 17, 2020

First Posted (Actual)

November 18, 2020

Study Record Updates

Last Update Posted (Actual)

November 18, 2020

Last Update Submitted That Met QC Criteria

November 17, 2020

Last Verified

November 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Dementia

Clinical Trials on Dog visit

Subscribe